September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Impact and safety of cefuroxime for post-operative endophthalmitis after cataract surgery: a national population study
Author Affiliations & Notes
  • Vincent Daien
    Ophthalmology, CHU Montpelliler, Saint Gely Du Fesc, France
    INSERM, Montpellier, France
  • Laurence PAPINAUD
    ERSM, Montpellier, France
  • Mark C Gillies
    Ophthalmology, Save Sight Institute, Sydney, Australian Capital Territory, Australia
  • Caroline DOMERG
    ERSM, Montpellier, France
  • Nicolas NAGOT
    INSERM, Montpellier, France
  • Sandy LACOMBE
    IURC, Montpellier, France
  • Jean Pierre DAURES
    IURC, Montpellier, France
  • Isabelle CARRIERE
    INSERM, Montpellier, France
  • Max Villain
    Ophthalmology, CHU Montpelliler, Saint Gely Du Fesc, France
  • Footnotes
    Commercial Relationships   Vincent Daien, None; Laurence PAPINAUD, None; Mark Gillies, None; Caroline DOMERG, None; Nicolas NAGOT, None; Sandy LACOMBE, None; Jean Pierre DAURES, None; Isabelle CARRIERE, None; Max Villain, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1990. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Vincent Daien, Laurence PAPINAUD, Mark C Gillies, Caroline DOMERG, Nicolas NAGOT, Sandy LACOMBE, Jean Pierre DAURES, Isabelle CARRIERE, Max Villain; Impact and safety of cefuroxime for post-operative endophthalmitis after cataract surgery: a national population study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1990.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Post-operative endophthalmitis (POE) is the most severe complication of the cataract surgery. Clinical trials have reported that intraocular cefuroxime administered at the conclusion of cataract surgery significantly lowered the risk of endophthalmitis. However, some surgeons still do not use this prophylactic antibiotic treatment in light of case reports of macular edema. The purpose of this study was to assess the impact and safety of cefuroxime for POE.

Methods : This is an observational, real-world, national population study, including all patients aged over 40 years who underwent primary cataract surgery in the 1,546 French healthcare facilities, public or private, from January 2010 to October 2014.

Results : From January 2010 to October 2014, 3,351,401 eyes of 2,434,008 patients ≥ 40 years old (58.9% women, mean age 73.9 ±9.5 years) underwent cataract surgery; 1,941 (0.08%) patients developed POE during the 6 weeks after cataract surgery. The incidence of POE after cataract surgery decreased over the course of the study: 0.11%, 0.09%, 0.08%, 0.06% and 0.05% in 2010, 2011, 2012, 2013 and 2014, respectively (p trend=0.001) as the use of cefuroxime prophylactic injection increased: 11.1%, 14.4%, 32.8%, 64.8% and 79.1% in 2010, 2011, 2012, 2013 and 2014, respectively (p trend=0.001). After multivariate adjustment, the risk of POE was reduced with the use of cefuroxime (OR 0.61; 95% CI 0.56 to 0.68). The retinal safety of cefuroxime, which was assessed by multi-adjusted odds of retinal cystoid macular edema, was not increased for patients receiving cefuroxime injections (OR 0.86; 95% CI 0.71 to 1.05).
In patients with perioperative capsular rupture of the lens (the major risk factor for POE which occurred in 0.14% of surgeries) and cefuroxime injection, POE incidence was lower than without cefuroxime (0.37% versus 0.51%, respectively, p=0.001), while the risk of cystoid macular edema was not significantly increased (5.6% with versus 7.3% without, respectively, p=0.12).

Conclusions : We found consistent evidence that intracameral cefuroxime administered at the conclusion of cataract surgery significantly lowers the risk of endophthalmitis and is safe in patients with or without perioperative capsular rupture in routine practice. This antibioprophylaxis should be considered for routine use to prevent POE, the most severe complication of cataract surgery.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×